- Title: Subtitle
- Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)
- Creators
- Panayiotis Savvides - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteSabarish Ayyappan - University Hospitals of ClevelandMin Yao - University Hospitals of ClevelandRod Rezaee - University Hospitals of ClevelandChad Zender - University Hospitals Case Medical CenterJay Wasman - University Hospitals of ClevelandPingfu Fu - University Hospitals of ClevelandMitchell Machtay - University Hospitals of ClevelandPierre Lavertu - University Hospitals of ClevelandMichael K. Gibson - University Hospitals of Cleveland
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.32(15_suppl), pp.6070-6070
- DOI
- 10.1200/jco.2014.32.15_suppl.6070
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2014
- Academic Unit
- Internal Medicine; Hematology, Oncology, and Blood & Marrow Transplantation
- Record Identifier
- 9984361570902771
Abstract
Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN)
Journal of clinical oncology, Vol.32(15_suppl), pp.6070-6070
05/20/2014
DOI: 10.1200/jco.2014.32.15_suppl.6070
Details
Metrics
9 Record Views